metaPreg - Daclizumab during pregnancy

Daclizumab updated on 06-01-2019

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	-	-	0 study					-
Major congenital malformations	-	-	0 study					-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	-	-	0 study					-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	-	-	0 study					-
Ectopic pregnancy	-	-	0 study					-
Elective/induced termination of pregnancy	-	-	0 study					-